文献速递心律失常

CABANA试验:年龄与导管消融对比药物治疗房颤的结局关联

Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.
PubMed 文献 · Circulation · 2021-12-22

CABANA随机试验纳入2204例房颤患者,按年龄分层分析导管消融对比药物治疗的结局。结果显示消融获益随年龄增长而减弱:<65岁患者主要终点事件风险降低43%,65-74岁降低21%,≥75岁未见明确获益(aHR 1.39)。治疗相关并发症各年龄组均低(<3%),房颤复发率消融在各年龄组均更低。

要点

  • 年轻房颤患者(<65岁)导管消融的主要终点相对获益最大(aHR 0.57)。
  • ≥75岁患者消融未见预后获益,主要终点aHR 1.39(95%CI 0.75-2.58)。
  • 各年龄组消融均降低房颤复发率,治疗并发症均<3%。

核心结论

  • 导管消融对比药物治疗的临床结局存在年龄相关差异,年轻患者相对和绝对获益最大,最年长患者未见预后获益。

研究设计与样本

  • CABANA随机试验,纳入房颤且≥65岁或<65岁伴≥1个卒中危险因素的患者2204例,随机分配至导管消融或药物治疗。
  • 按入组年龄分层:<65岁766例(34.8%),65-74岁1130例(51.3%),≥75岁308例(14.0%)。

主要发现

  • 主要终点(死亡、致残性卒中、严重出血或心脏骤停复合终点):<65岁aHR 0.57(95%CI 0.30-1.09),65-74岁aHR 0.79(95%CI 0.54-1.16),≥75岁aHR 1.39(95%CI 0.75-2.58)。
  • 4年主要终点事件率消融vs药物:<65岁3.2% vs 7.8%,65-74岁7.8% vs 9.6%,≥75岁14.8% vs 9.0%。
  • 年龄每增加10岁,主要终点aHR平均增加27%(交互P=0.215);全因死亡aHR平均增加46%(交互P=0.111)。
  • 房颤复发率消融低于药物,各年龄亚组aHR分别为0.47、0.58、0.49。
  • 治疗相关并发症两臂均不常见(<3%),与年龄无关。

临床怎么用

  • 对年轻房颤患者,导管消融可作为改善预后的重要选择。
  • 对≥75岁患者,消融的预后获益不明确,决策需综合评估。
  • 各年龄组消融均能降低房颤复发,且并发症发生率低。

局限性

  • 年龄亚组分析为事后分析,交互检验P值未达统计学显著性(主要终点P=0.215,全因死亡P=0.111)。
  • ≥75岁亚组样本量较小(308例),结果置信区间宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational data suggest that catheter ablation may be safe and effective to treat younger and older patients with atrial fibrillation. No large, randomized trial has examined this issue. This report describes outcomes according to age at entry in the CABANA trial (Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation). METHODS: Patients with atrial fibrillation ≥65 years of age, or <65 with ≥1 risk factor for stroke, were randomly assigned to catheter ablation versus drug therapy. The primary outcome was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Secondary outcomes included all-cause mortality, the composite of mortality or cardiovascular hospitalization, and recurrence of atrial fibrillation. Treatment effect estimates were adjusted for baseline covariables using proportional hazards regression models. RESULTS: Of 2204 patients randomly assigned in CABANA, 766 (34.8%) were <65 years of age, 1130 (51.3%) were 65 to 74 years of age, and 308 (14.0%) were ≥75 years of age. Catheter ablation was associated with a 43% reduction in the primary outcome for patients <65 years of age (adjusted hazard ratio [aHR], 0.57 [95% CI, 0.30-1.09]), a 21% reduction for 65 to 74 years of age (aHR, 0.79 [95% CI, 0.54-1.16]), and an indeterminate effect for age ≥75 years of age (aHR, 1.39 [95% CI, 0.75-2.58]). Four-year event rates for ablation versus drug therapy across age groups, respectively, were 3.2% versus 7.8%, 7.8% versus 9.6%, and 14.8% versus 9.0%. For every 10-year increase in age, the primary outcome aHR increased (ie, less favorable to ablation) an average of 27% (interaction P value=0.215). A similar pattern was seen with all-cause mortality: for every 10-year increase in age, the aHR increased an average of 46% (interaction P value=0.111). Atrial fibrillation recurrence rates were lower with ablation than with drug therapy across age subgroups (aHR 0.47, 0.58, and 0.49, respectively). Treatment-related complications were infrequent for both arms (<3%) regardless of age. CONCLUSIONS: We found age-based variations in clinical outcomes for catheter ablation compared with drug therapy, with the largest relative and absolute benefits of catheter ablation in younger patients. No prognostic benefits for ablation were seen in the oldest patients. No differences were found by age in treatment-related complications or in the relative effectiveness of catheter ablation in preventing recurrent atrial arrhythmias. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00911508.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bahnson, Giczewska, Mark, et al. Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. Circulation. 2021. PMID: 34933570. doi:10.1161/CIRCULATIONAHA.121.055297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。